JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety ...

First approved in 2o12, Xeljanz brought in sales of more than $1.7 billion in the first nine months of 2020, up 10% overall and 23% in ex-US markets. It has maintained steady sales growth despite ...